Key Highlights

  • Jasper's BEACON study showed 83% of patients achieving a complete response by week three on a 240mg/180mg every-eight-weeks dosing cohort.
  • An open-label extension in 36 chronic spontaneous urticaria patients showed 58% achieving complete response at 12 weeks.
  • The company expects to begin a Phase 2b CSU study in the second half of 2026.
  • JSPR shares slid despite the encouraging data, as investors weighed the Capital needed to fund the upcoming pivotal-style trial.

Jasper Therapeutics, Inc. (NASDAQ:JSPR), a clinical-stage biotechnology company developing its antibody briquilimab across allergic and inflammatory diseases, saw its shares slide even as it attracted a bullish analyst stance and reported updated data supporting dose selection ahead of a pivotal-style study. The decline raises the question of what is weighing on sentiment despite the encouraging clinical progress.

Briquilimab targets c-Kit, a receptor implicated in the activity of mast cells, which drive conditions such as chronic urticaria (hives) and asthma. Jasper's thesis is that by depleting or modulating these cells, briquilimab can deliver durable disease control with convenient, infrequent dosing, an appealing profile in large markets where patients seek alternatives to existing therapies.

Latest developments

Jasper has reported encouraging updated results from its briquilimab studies in chronic spontaneous urticaria (CSU). In its BEACON study, additional patients in a 240mg/180mg every-eight-weeks cohort showed 83% achieving a complete response by week three, with 67% maintaining a complete response at 12 weeks and a mean UAS7 (disease-activity score) reduction of 31 points. An open-label extension in 36 CSU patients showed 58% achieving complete response and 75% reaching complete response or well-controlled disease at 12 weeks on 180mg every eight weeks.

The company said it now has sufficient efficacy and safety data to enable dose selection and expects to begin a Phase 2b CSU study in the second half of 2026.

Financial and Business position

As a clinical-stage company, Jasper's value rests on advancing briquilimab through increasingly definitive trials, which requires substantial capital over multi-year timelines. The reported KIT-related adverse events have been described as infrequent and low-grade, an important consideration for a chronic therapy, but tolerability and efficacy must be confirmed in larger, controlled studies.

Stock-market context

JSPR shares slid even as the stock carries a strong-buy rating in the underlying data, reflecting optimism about briquilimab's differentiated dosing and the consistency of its early urticaria data. The decline may reflect investor caution about the capital needed to fund the upcoming Phase 2b study; the risk case is that mid-stage data can disappoint, and that a capital raise could pressure the shares further even amid clinical progress.

What investors should watch

Investors may focus on the launch of the Phase 2b CSU study in the second half of 2026, the selected dose and trial design, further data in chronic inducible urticaria and asthma, tolerability across larger patient groups, and the company's cash position.

Encouraging Data, a Cautious Market

The commercial opportunity behind briquilimab is substantial because chronic urticaria and asthma are large markets where many patients remain inadequately controlled on existing therapies. The essential caveat is that open-label and early-phase results, however encouraging, must be confirmed in larger, randomized, controlled trials before they can support approval, and the upcoming Phase 2b study is the pivotal test that will do far more to determine the stock's direction than any prior signal.